Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781500 | 0.94 | CHRM4 (0.40) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5781595 | 0.93 | NMT1 (0.41) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5778143 | 0.92 | NMT1 (0.40) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5782171 | 0.85 | MCHR1 (0.40) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5781748 | 0.85 | DRD2 (0.41) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5800721 | 0.85 | MCHR1 (0.43) | FAAHCHRM4L3MBTL1MCHR1 | |
| SCHEMBL5779441 | 0.85 | MCHR1 (0.41) | FAAHCHRM4L3MBTL1MCHR1DRD2 | |
| SCHEMBL5779367 | 0.85 | DRD2 (0.38) | MCHR1DRD2HTR2ADRD3 | |
| SCHEMBL6893592 | 0.83 | DRD2 (0.41) | FAAHCHRM4DRD2DRD3 | |
| SCHEMBL5782670 | 0.83 | CHRM4 (0.40) | FAAHCHRM4L3MBTL1MCHR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | FAAH 646/4885CHRM4 887/4885L3MBTL1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.